Intract is a oral biologics drug delivery platform company focusing on lower gastrointestinal tract targeting of monoclonal antibodies, fusion proteins, cytokines and peptide therapeutics for local GI and systemic response. The company has 8 active partnered programs in pre-clinical stag and is looking to raise $20m Series A funding to enable scale-up of the platform and take it to Phase 2a PoC stage.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
United Kingdom
Year Founded:
2016
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
Oral delivery technology for antibody in inflammatory bowel disease
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
